Junshi’s JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that its Phase 3 trial JS001sc-002-III-NSCLC...
Junshi Biosciences
Shanghai Junshi Biosciences Secures First Canadian Approval for LOQTORZI (Toripalimab) in Nasopharyngeal Cancer
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced today that its programmed death‑1...
Junshi Biosciences Q3 2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today released its third‑quarter 2025 financial results....
Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase II/III Trial
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today announced that the U.S. Food...
Junshi Biosciences Reports 49 % YoY Revenue Growth in H1 2025, Raises Cash Reserves to RMB 3.49 B
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today released its 2025 interim financial...
Shanghai Junshi Biosciences Announces Nearly RMB 380 Million Capital Increase for Grit Biotechnology
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) disclosed that its subsidiary, Shanghai JunTop...
Junshi Biosciences’ JS005 IL‑17A Antibody Shows Promise in Phase III Psoriasis Trial
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that its proprietary recombinant humanized...
JT118 Vaccine Receives NMPA Approval for Monkeypox Prevention
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that China’s National Medical Products...
Junshi Biosciences’ Toripalimab Receives NMPA Acceptance for HER2-expressing UC Treatment
China’s Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...
Junshi Biosciences’ Junshida Wins NMPA Approval for HeFH and Statin-Intolerant Patients
China’s Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...
Shanghai Junshi Biosciences’ Loqtorzi Receives NMPA Approval for Melanoma Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received another...
Shanghai Junshi Biosciences’ Loqtorzi Approved in Singapore for Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval from...
Shanghai Junshi Biosciences’ Loqtorzi Approved for Hepatocellular Carcinoma Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving approval from the...
Junshi Biosciences Receives NMPA Approval for JS213 Clinical Trials
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...
Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms
China-based Tofflon Science and Technology Group Co., Ltd. (SHE: 300171), a total solution service provider...
Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement...
Junshi Biosciences Forecasts 29.71% Revenue Growth for 2024
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has released its 2024 annual...
Junshi Biosciences’ Toripalimab Gains TGA Approval for Nasopharyngeal Carcinoma
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval...
Junshi Biosciences’ Loqtorzi Gains Regular Approval for Melanoma Treatment in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its PD-1 inhibitor,...
Shanghai Junshi Biosciences Enters Licensing Agreement for Dual-Targeted Fusion Proteins
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a China-based biopharmaceutical company, has announced...